The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice. Aim. The main objective of this retrospective observational study was to evaluat...

Full description

Bibliographic Details
Main Authors: Elena I. Kovalenko, Elena V. Artamonova, Elena V. Karabina, Irina I. Andreiashkina, Ekaterina A. Prokof’eva, Nataliia O. Popova, Elena A. Gaisina, Irina V. Evstigneeva, Mikhail V. Shaidorov, Larisa A. Zhiliaeva, Dmitrii M. Ponomarenko, Alfiia I. Khasanova, Guzel Z. Mukhametshina, Anton E. Koziakov, Liudmila V. Vorotilina, Anton Iu. Povyshev, Elena I. Simolina, Vasilii V. Marfutov, Dmitrii V. Kozlov, Irina R. Suslova, Valentina E. Shikina, Tatiana V. Karandeeva, Artem O. Shepel’, Liudmila V. Kramskaia, Denis A. Oskirko, Olga S. Frolova
Format: Article
Language:Russian
Published: IP Habib O.N. 2020-05-01
Series:Современная онкология
Subjects:
breast cancer
eribulin
efficacy
tolerance
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/34173/22585

Similar Items

Similar Items